Weiss Multi-Strategy Advisers’s Rigel Pharmaceuticals RIGL Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,128	Closed	-$147K	–	386
2023 Q4	$147K	Sell	10,128 -1,787	-15%	-$18.3K	﹤0.01%	515
2023 Q3	$129K	Sell	11,915 -1,403	-11%	-$16.9K	﹤0.01%	523
2023 Q2	$172K	Sell	13,318 -1,375	-9%	-$18.6K	﹤0.01%	608
2023 Q1	$194K	Sell	14,693 -268	-2%	-$4.26K	﹤0.01%	590
2022 Q4	$224K	Sell	14,961 -4,539	-23%	-$41.6K	0.01%	543
2022 Q3	$230K	Sell	19,500 -1,500	-7%	-$20.3K	0.01%	601
2022 Q2	$237K	Sell	21,000 -8,807	-30%	-$177K	0.01%	604
2022 Q1	$891K	Sell	29,807 -8,193	-22%	-$222K	0.02%	516
2021 Q4	$1.01M	Sell	38,000 -2,621	-6%	-$79.1K	0.02%	476
2021 Q3	$1.48M	Buy	40,621 +743	+2%	+$29.2K	0.03%	457
2021 Q2	$1.73M	Buy	39,878 +1,278	+3%	+$48.3K	0.04%	423
2021 Q1	$1.32M	Sell	38,600 -5,576	-13%	-$221K	0.03%	455
2020 Q4	$1.55M	Sell	44,176 -5,191	-11%	-$150K	0.03%	448
2020 Q3	$1.19M	Sell	49,367 -487	-1%	-$12K	0.03%	407
2020 Q2	$912K	Buy	49,854 +1,700	+4%	+$30.6K	0.03%	418
2020 Q1	$751K	Sell	48,154 -1,846	-4%	-$39.3K	0.03%	322
2019 Q4	$1.07M	Sell	50,000 -1,000	-2%	-$20.6K	0.02%	484
2019 Q3	$954K	Hold	51,000	–	–	0.02%	451
2019 Q2	$1.33M	Hold	51,000	–	–	0.04%	353
2019 Q1	$1.31M	Hold	51,000	–	–	0.03%	367
2018 Q4	$1.17M	Buy	51,000 +1,500	+3%	+$42.3K	0.05%	283
2018 Q3	$1.59M	Buy	49,500 +4,390	+10%	+$132K	0.04%	360
2018 Q2	$1.28M	Buy	45,110 +18,110	+67%	+$644K	0.03%	412
2018 Q1	$956K	Sell	27,000 -3,000	-10%	-$120K	0.03%	422
2017 Q4	$1.16M	Buy	30,000 +23,200	+341%	+$883K	0.03%	426
2017 Q3	$173K	Hold	6,800	–	–	0.01%	461
2017 Q2	$186K	Sell	6,800 -200	-3%	-$5.47K	0.01%	496
2017 Q1	$232K	Hold	7,000	–	–	0.01%	513
2016 Q4	$167K	Sell	7,000 -500	-7%	-$14.3K	0.01%	386
2016 Q3	$275K	Sell	7,500 -10,725	-59%	-$307K	0.02%	381
2016 Q2	$406K	Sell	18,225 -12,275	-40%	-$305K	0.03%	338
2016 Q1	$634K	Hold	30,500	–	–	0.03%	374
2015 Q4	$924K	Buy	30,500 +100	+0.3%	+$3.03K	0.06%	248
2015 Q3	$751K	Buy	30,400 +400	+1%	+$11.9K	0.03%	285
2015 Q2	$963K	Buy	30,000 +7,000	+30%	+$267K	0.04%	320
2015 Q1	$821K	Buy	23,000 +1,000	+5%	+$27.4K	0.04%	334
2014 Q4	$499K	Buy	22,000 +7,000	+47%	+$142K	0.02%	343
2014 Q3	$291K	Hold	15,000	–	–	0.01%	477
2014 Q2	$545K	Hold	15,000	–	–	0.01%	512
2014 Q1	$582K	Buy	15,000 +11,032	+278%	+$393K	0.01%	612
2013 Q4	$113K	Buy	+3,968	New	+$116K	﹤0.01%	935
2013 Q3	–	Sell	-5,000	Closed	-$167K	–	987
2013 Q2	$167K	Buy	+5,000	New	+$227K	﹤0.01%	721

Other funds holding RIGL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Weiss Multi-Strategy Advisers's RIGL Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Rigel Pharmaceuticals (RIGL) in Q1 2024, closing a stake of 10,128 shares — an estimated $147K sold.

Weiss Multi-Strategy Advisers first reported a position in RIGL in Q2 2013 and held it in 42 quarters. The position peaked at $1.73M in Q2 2021. 117 funds tracked by Wall St. Rank hold RIGL as of Q1 2024.

Weiss Multi-Strategy Advisers reported no remaining Rigel Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 10,128 Rigel Pharmaceuticals shares in Q1 2024, an estimated $147K.
Weiss Multi-Strategy Advisers first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 42 quarters.
Weiss Multi-Strategy Advisers's Rigel Pharmaceuticals position peaked at $1.73M in Q2 2021.
117 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.